Lovotibeglogene autotemcel
PreclinicalCell therapy
BiogenLovotibeglogene autotemcel is a cell therapy that works as a BCL11A Shrna Gene Therapy.[1] It is being investigated across 1 indication, with its most advanced program in Preclinical.
Lovotibeglogene autotemcel is one of 41 gene therapy programs targeting Sickle Cell Disease. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[2]
Indication
Competition
Competitive Landscape
272 competitors in Sickle Cell Disease
#DrugCompanyPhaseTrials
1Adakveo
NovartisPhase 3
Exjade
NovartisPhase 3
Brilinta
AstraZenecaPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Cysteine Hydrochloride
NovartisPhase 3
Ritalin
NovartisPhase 3
Eliquis
Bristol-Myers SquibbPhase 3
Oxbryta
GGlobal Blood Therapeutics
Phase 3
Aqvesme
AAgios Pharmaceuticals, Inc.
Phase 3
Effient
CCosette Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Lovotibeglogene autotemcel. EMBL-EBI & Wellcome Sanger Institute.
- [3]